Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infection
Authors:
- 21 January 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (3) , 248
Abstract
This JAMA Guidelines Synopsis summarizes the 2024 Centers for Disease Control and Prevention guidelines on use of doxycycline postexposure prophylaxis (doxyPEP) for bacterial sexually transmitted infection prevention.Keywords
This publication has 8 references indexed in Scilit:
- CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024MMWR. Recommendations and Reports, 2024
- Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial designThe Lancet Infectious Diseases, 2024
- Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted InfectionsClinical Infectious Diseases, 2024
- Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in WomenNew England Journal of Medicine, 2023
- Vital Signs: Missed Opportunities for Preventing Congenital Syphilis — United States, 2022MMWR. Morbidity and Mortality Weekly Report, 2023
- A Genomic Perspective on the Near-term Impact of Doxycycline Post-exposure Prophylaxis on Neisseria gonorrhoeae Antimicrobial ResistanceClinical Infectious Diseases, 2023
- Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted InfectionsNew England Journal of Medicine, 2023
- Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trialThe Lancet Infectious Diseases, 2018